Epilepsy Risk and Your Genetics

By the ExomeDNA Science Team | This page contains general information only. For personal health decisions, consult a qualified clinician.

Epilepsy risk is shaped by a complex web of inherited genetic variants, and genome-wide association studies now implicate more than 26 distinct genomic loci in common epilepsy susceptibility. Below, this page explains the science behind genetic epilepsy risk, what the research says about polygenic contributions, how specific genes shape neural circuit stability, and what lifestyle factors interact with genetic predisposition.

What is epilepsy risk?

Epilepsy is not a single disease. It is a spectrum of neurological conditions unified by one defining feature: recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. According to the World Health Organization, epilepsy affects approximately 50 million people worldwide, making it one of the most common serious neurological conditions globally.

A seizure occurs when a sudden, synchronized burst of electrical signals disrupts normal brain activity. Depending on which brain regions are involved, a person may experience convulsions, brief lapses in awareness, sensory disturbances, or other transient neurological changes. Most seizures last between 30 seconds and two minutes and resolve on their own.

Epilepsy risk has a meaningful heritable component. For the common, non-lesional epilepsies captured by GWAS research, heritability estimates typically fall in the 26–40% range. For certain rare, highly penetrant genetic epilepsies, heritability approaches 100%. The ExomeDNA result for this trait focuses on the polygenic contribution to common epilepsy susceptibility — the cumulative effect of many common genetic variants, each individually small, that together shift the population distribution of seizure threshold.

Critically, a polygenic risk score for epilepsy does not indicate that epilepsy is present or certain. Seizure threshold varies across individuals and changes across the lifespan. Many people with elevated polygenic risk never experience a seizure. The score is a probabilistic signal, not a clinical verdict.

The genetics behind epilepsy risk

Common epilepsy GWAS, including the landmark 2023 meta-analysis published by the International League Against Epilepsy (ILAE) Consortium on Complex Epilepsies (PMID 37653029), have now identified 26 genome-wide significant risk loci across more than 29,000 people with epilepsy and over 52,000 controls. Earlier ILAE mega-analyses — including the 2018 study identifying 16 loci (PMID 30531953) and the 2014 meta-analysis of common epilepsies (PMID 25087078) — built the evidentiary foundation for this expanding genetic map.

Several genes at or near these loci play mechanistically interpretable roles in neural circuit development and function. ExomeDNA's epilepsy risk score incorporates variants in the following authorized genes:

BCL11A is a C2H2 zinc-finger transcription factor known primarily for its role in regulating the fetal-to-adult hemoglobin switch, but it is also expressed in developing brain tissue where it specifies GABAergic interneuron subtypes and guides cortical circuit formation. GABAergic interneurons are the brain's primary inhibitory neurons — they act as the braking system for cortical excitability. When interneuron specification is disrupted, the balance between neural excitation and inhibition can shift, raising the probability of runaway excitatory activity that manifests as a seizure.

CUX2 encodes the cut-like homeobox 2 transcription factor, which is expressed specifically in upper-layer cortical neurons occupying layers II and III. These neurons form the cortico-cortical connections that integrate information across brain regions. CUX2 regulates dendrite branching, spine density, and synaptic connectivity in these circuits. De novo mutations in CUX2 cause severe epileptic encephalopathy; common variants near the gene may influence cortical circuit efficiency and seizure threshold in the general population.

ADGRL3 (latrophilin-3, formerly LPHN3) is an adhesion G protein-coupled receptor that forms transsynaptic protein complexes at excitatory synapses alongside FLRT3 and teneurin. These scaffolds regulate synapse formation, maturation, and strength. Because the excitatory-inhibitory (E/I) balance at individual synapses propagates into circuit-level excitability, variants that alter ADGRL3-mediated synapse organization can shift the system-level seizure threshold. ADGRL3 variants have been associated with both ADHD and epilepsy in genetic studies.

ALDH2 encodes mitochondrial aldehyde dehydrogenase 2, the enzyme primarily responsible for metabolizing acetaldehyde after alcohol consumption and for clearing reactive aldehydes — including 4-hydroxynonenal (4-HNE) and malondialdehyde — generated during neuronal oxidative stress. The ALDH2*2 variant (rs671), prevalent in approximately 35% of East Asian populations, reduces enzyme activity by roughly 90%. Impaired clearance of neurotoxic aldehydes both lowers seizure threshold directly and amplifies the seizure-precipitating effect of alcohol. A 2021 Japanese GWAS (PMID 33913524) identified ALDH2-region variants in an East Asian epilepsy cohort, adding population-specific evidence to this mechanism.

EXT1 encodes exostosin glycosyltransferase 1, the enzyme responsible for biosynthesizing heparan sulfate proteoglycans (HSPGs). While pathogenic EXT1 mutations are known for causing hereditary multiple exostoses (bone tumors), EXT1 expression in the brain contributes to HSPG scaffolds that organize GABAergic synapses, guide axon pathfinding, and regulate synaptogenesis. Disruption of HSPG architecture at GABAergic synapses can reduce inhibitory tone and thereby elevate seizure susceptibility.

BRD7 is a bromodomain-containing subunit of the PBAF SWI/SNF chromatin remodeling complex — an epigenetic regulator with emerging roles in neural development and transcriptional control of excitability circuits.

BRAP (BRCA1-associated protein) is an E3 ubiquitin ligase involved in Ras/MAPK pathway regulation, associated with cardiovascular and metabolic traits. Its epilepsy locus contribution reflects the broader pleiotropic landscape of common genetic variation.

Together, these genes share a unifying theme: the excitatory-inhibitory balance. BCL11A and EXT1 operate on GABAergic inhibitory infrastructure. CUX2 and ADGRL3 shape excitatory synaptic architecture. ALDH2 modulates the neurochemical environment. Perturbing any of these via common variants produces a subtle shift in seizure threshold — a changed probability landscape, not a guarantee of seizures.

What the research says

Robust evidence from multiple large-scale GWAS meta-analyses supports a polygenic architecture for common epilepsy.

The 2018 ILAE mega-analysis (PMID 30531953) identified 16 genome-wide significant loci across 15,212 people with epilepsy and 29,677 controls, demonstrating that common epilepsies share genetic architecture with each other and, in part, with other neurological and psychiatric conditions. This study established that focal and generalized epilepsies — traditionally classified as clinically distinct — share a meaningful proportion of their genetic risk.

The 2023 ILAE meta-analysis (PMID 37653029) extended this to 29,944 epilepsy cases and 52,538 controls, identifying 26 independent risk loci — nearly doubling the genetic map in five years. Noteworthy findings include genes active in neurodevelopmental pathways, synaptic transmission, and ion channel regulation. Genetic correlation analyses found overlap with depression, anxiety, ADHD, and migraine — consistent with shared neural excitability mechanisms across these conditions.

A cross-population atlas of 220 phenotypes (PMID 34594039) found that some epilepsy-associated variants, including those near ALDH2, have different allele frequencies and effect sizes across ancestries — important context for polygenic score interpretation.

Two additional studies published in 2021 (PMIDs 33913524 and 34456681) contributed a Japanese-population GWAS identifying ancestry-specific loci and a global meta-analysis identifying two novel risk loci, respectively, further broadening the genetic landscape of epilepsy susceptibility.

Key quantitative benchmarks:

1. Heritability of common epilepsy: 26–40% (twin and GWAS-based methods)
2. 26 genome-wide significant loci as of the 2023 ILAE meta-analysis, up from 16 in 2018
3. ALDH2*2 reduces aldehyde dehydrogenase activity ~90%; carried by ~35% of East Asian individuals
4. ~70% of people with newly identified epilepsy achieve seizure freedom with antiseizure medication
5. Polygenic risk scores explain a modest fraction of population variance — epilepsy risk is distributed across many variants of small effect

How epilepsy risk affects you

Epilepsy is one of the most treatable serious neurological conditions. Approximately 70% of people with epilepsy achieve complete seizure control with medication, and another meaningful proportion can reduce or eliminate medication over time. That said, epilepsy carries real-world implications: driving restrictions, swimming safety, workplace accommodations, and sleep needs are practical concerns. Stigma persists in many cultural contexts, often out of proportion to actual functional impairment.

For individuals with elevated genetic risk who do not have an epilepsy finding, the clinical relevance is probabilistic rather than deterministic. Genetic risk variants shift seizure threshold — they do not override the many protective factors that keep threshold high enough to prevent spontaneous seizures in most people. Environmental and behavioral factors that lower seizure threshold interact with genetic predisposition:

• Sleep deprivation is one of the most reliable seizure precipitants across all epilepsy types. Even a single night of significantly disrupted sleep can transiently lower seizure threshold in susceptible individuals.
• Alcohol consumption lowers seizure threshold through multiple mechanisms — GABA receptor modulation, electrolyte shifts, and aldehyde accumulation. For individuals carrying the ALDH2*2 variant, this effect is amplified because impaired aldehyde clearance extends neurotoxic exposure.
• Stress and cortisol dysregulation affect limbic excitability and are recognized seizure precipitants, particularly for temporal lobe seizure foci.
• Photosensitivity — identifiable by EEG — is present in a subset of people with epilepsy and may have its own distinct genetic architecture.
• Fever and systemic illness transiently raise neural excitability and precipitate febrile seizures in predisposed children; fever can also precipitate breakthrough seizures in adults with known epilepsy.

A family history of epilepsy — particularly first-degree relatives with generalized epilepsy — meaningfully increases risk independently of any polygenic score and should factor into any neurological evaluation.

Working with your epilepsy risk result

For individuals reviewing their genetic risk result for epilepsy, the following prioritized steps provide a structured way to think about what the information means in practice:

1. Contextualize the score against your clinical history. If no seizures or seizure-like episodes have occurred, a modestly elevated polygenic risk score is probabilistic background information, not a finding. If seizures, blank spells, or unexplained episodic neurological events have occurred, discuss the result with a neurologist.

2. Prioritize sleep. Sleep deprivation is among the most modifiable seizure precipitants. Consistent sleep timing, adequate duration (seven to nine hours for most adults), and treatment of sleep-disordered breathing where present are high-yield interventions.

3. Moderate alcohol consumption — especially if you carry ALDH2*2. If your ancestry is East Asian and you experience facial flushing after alcohol, you likely carry the ALDH22 variant. Alcohol is a reliable seizure precipitant through multiple mechanisms; for ALDH22 carriers, the threshold for alcohol-related neurological effects is lower. Limiting or avoiding alcohol is a direct risk-reduction strategy.

4. Know your family history. First-degree relatives with epilepsy — particularly generalized epilepsies with known genetic architecture (juvenile myoclonic epilepsy, childhood absence epilepsy) — meaningfully inform your own prior risk and are worth documenting for any neurology consultation.

5. Maintain medication adherence for those with a finding. For people already identified with epilepsy, medication adherence is the strongest modifiable predictor of seizure control. Missing doses is the leading cause of breakthrough seizures in well-controlled epilepsy.

6. Understand SUDEP awareness. Sudden unexpected death in epilepsy (SUDEP) is rare — roughly 1 in 1,000 person-years, higher for those with poorly controlled seizures. Monitoring, medication adherence, and avoiding prone sleep reduce risk. Relevant primarily for people with a confirmed epilepsy finding and their caregivers.

Related traits and genes

Brain & Mental Health siblings. Epilepsy risk shares genetic architecture with several other traits in the Brain & Mental Health category. Anxiety Predisposition overlaps through shared neural excitability pathways — the 2023 ILAE meta-analysis identified genetic correlation with anxiety disorders. Sleep Duration and Sleep Depth are directly relevant because sleep quality is both a seizure precipitant and a trait with partially overlapping neural circuit genetics.

Cross-category connections. The ALDH2 gene appears in both the Epilepsy Risk analysis and in traits related to alcohol metabolism and oxidative stress response, which span the Metabolism & Hormones and Drug & Medication Response categories. Individuals with ALDH2*2 variants should consider how their result in this category interacts with any relevant results in those categories. Cardiovascular Health traits also share genetic architecture with neurological risk through pleiotropic variants near BRAP and related Ras/MAPK pathway genes.

Gene-level context. The BCL11A gene is best known for its role in hemoglobin switching and appears in research on red blood cell traits; its brain-expressed role in GABAergic interneuron development is an active area of neuroscience research. CUX2 variants associated with cortical circuit architecture also appear in cognitive performance research, connecting epilepsy neurobiology to broader cortical function.

Frequently asked questions

Does a high epilepsy risk score mean I will develop epilepsy? No. A high polygenic risk score indicates that your inherited genetic variants collectively place you toward the higher end of the population distribution for seizure threshold variation. Most people with elevated genetic risk never experience a seizure. The score reflects probability, not destiny. Environmental, behavioral, and clinical factors all modify whether genetic predisposition translates into clinical epilepsy.

What causes epilepsy beyond genetics? Epilepsy can arise from many causes: acquired brain injury (head trauma, stroke, infection), structural abnormalities identified on brain MRI, immune-mediated encephalitis, metabolic disturbances, and de novo mutations not inherited from parents. The polygenic risk captured in this trait relates specifically to inherited common variants, not to acquired or de novo causes.

Which ancestry groups are most affected by ALDH2-related epilepsy risk? The ALDH22 variant (rs671) is most prevalent in East Asian populations — approximately 30–40% of individuals of Chinese, Japanese, and Korean ancestry carry at least one copy. The enzyme activity reduction in ALDH22 carriers is relevant to both alcohol-related seizure risk and broader neuronal oxidative stress vulnerability. The 2021 Japanese-population GWAS (PMID 33913524) specifically identified ALDH2-region associations in this ancestry context.

Can children of a parent with epilepsy use this information? Family history and polygenic risk scores are complementary but distinct signals. A parent with epilepsy raises a child's risk through both shared common variants (captured partly by the polygenic score) and potentially through rare variants not captured in common-variant GWAS. Children of parents with generalized epilepsies have roughly 2–10% lifetime risk depending on epilepsy type — substantially higher than the general population rate of about 1–3%.

How does sleep affect epilepsy risk? Sleep deprivation is one of the most reproducible and powerful seizure precipitants known. Sleep transitions — particularly the shift from wakefulness to sleep and from sleep to waking — are periods of heightened cortical excitability. Many people with epilepsy report that poor sleep reliably precedes breakthrough seizures. Good sleep hygiene is therefore a direct, actionable risk-reduction strategy regardless of genetic risk tier.

Is epilepsy treatable? Epilepsy is among the more treatable serious neurological conditions. Approximately 70% of people with a new epilepsy finding achieve complete seizure freedom with their first or second antiseizure medication. For those who do not respond to medication (drug-resistant epilepsy), surgical evaluation, dietary therapies (ketogenic diet), nerve stimulation devices, and emerging gene-targeted therapies provide additional options. The prognosis for quality of life with optimal treatment is substantially better than many people assume.

References

1. Guo Y, et al. Two-stage genome-wide association study identifies variants in CAMSAP1L1 as susceptibility loci for epilepsy. Human Molecular Genetics. 2012. PMID 22116939.
2. International League Against Epilepsy Consortium on Complex Epilepsies. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurology. 2014. PMID 25087078.
3. International League Against Epilepsy Consortium on Complex Epilepsies. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nature Communications. 2018. PMID 30531953.
4. Suzuki T, et al. Genome-wide association study of epilepsy in a Japanese population identified an independent risk locus at 2p16.1. Journal of Human Genetics. 2021. PMID 33913524.
5. Song M, et al. Genome-Wide Meta-Analysis Identifies Two Novel Risk Loci for Epilepsy. Frontiers in Neuroscience. 2021. PMID 34456681.
6. Sakaue S, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nature Genetics. 2021. PMID 34594039.
7. International League Against Epilepsy Consortium on Complex Epilepsies. GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific risk variants. Nature Genetics. 2023. PMID 37653029.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.